Guided Therapeutics (GTHP) Accounts Payables (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Accounts Payables data on file, last reported at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 15.38% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (up 15.38% YoY), and the FY2025 full-year result was $2.4 million, up 15.38% from the prior year.
• Accounts Payables advanced to $2.4 million in Q4 2025, from $2.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.5 million in Q1 2022 to a low of $1.9 million in Q1 2024.
• A 5-year average of $2.2 million and a median of $2.2 million in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables dropped 14.91% in 2021 and rose 15.38% in 2025, its largest moves.
• Tracing GTHP's Accounts Payables over 5 years: stood at $2.4 million in 2021, then dropped by 7.45% to $2.2 million in 2022, then slipped by 8.92% to $2.0 million in 2023, then grew by 5.17% to $2.1 million in 2024, then climbed by 15.38% to $2.4 million in 2025.
• Business Quant data shows GTHP's Accounts Payables at $2.4 million in Q4 2025, $2.4 million in Q3 2025, and $2.3 million in Q2 2025.